The findings were published in the journal JAMA Ophthalmology
Initial clinical findings suggest that GLP-1 receptor agonists could provide an effective therapeutic strategy in patients with AD and those at risk, however, there remains a lack of sufficient evidence in large clinical samples to draw any firm conclusions
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-IRAs, GLP-1 analogs, or incretin mimetics, are a class of medications that activate the GLP-1 receptor, leading to reduced blood sugar levels and decreased appetite, which in turn results in lower energy intake
Complicated enrollment and onboarding: Small business owners often manage the paperwork themselves, which can take 30 or more hours over many weeks, every year
No video visit required